H.C. Wainwright initiated coverage of NeuroPace (NPCE) with a Buy rating and $18 price target NeuroPace is a commercial-stage medical device company focused on the development and marketing of a brain-responsive neuromodulation system that can deliver personalized, real-time treatment at the seizure source for patients with drug-resistant focal epilepsy, the analyst tells investors in a research note. The firm says the cutback after the one-year data readout from the NAUTILUS study presents an attractive entry point, as the data have no impact on the sales momentum in patients with focal epilepsy.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- NeuroPace: Buy Rating Affirmed Amid Promising NAUTILUS Study Outcomes and Favorable FDA Engagement
- Optimistic Outlook for NeuroPace: Buy Rating Justified by Subgroup Success and Growth Potential
- NeuroPace’s Promising Prospects: Buy Rating Affirmed Despite Initial Study Setback
- Leerink says NeuroPace results disappointing, sees hope on totality of data
- NeuroPace Announces Promising NAUTILUS Study Results